Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Gress Website

Ronald E. Gress, M.D.

Selected Publications

1)  Flomerfelt FA, El Kassar N, Gurunathan C, Chua KS, League SC, Schmitz S, Gershon TR, Kapoor V, Yan XY, Schwartz RH, Gress RE.
Tbata modulates thymic stromal cell proliferation and thymus function.
J. Exp. Med. 207: 2521-32, 2010.
[Journal]
2)  Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
J. Exp. Med. 205: 1701-14, 2008.
[Journal]
3)  Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C, Odom J, Vance BA, Christensen BL, Mackall CL, Gress RE.
Age-dependent incidence, time course, and consequences of thymic renewal in adults.
J. Clin. Invest. 115: 930-9, 2005.
[Journal]
4)  Lucas PJ, Kim SJ, Melby SJ, Gress RE.
Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor.
J. Exp. Med. 191: 1187-96, 2000.
[Journal]
5)  Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM.
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.
N. Engl. J. Med. 332: 143-9, 1995.
[Journal]
6)  Imanguli MM, Cowen EW, Rose J, Dhamala S, Swaim W, Lafond S, Yagi B, Gress RE, Pavletic SZ, Hakim FT.
Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.
Leukemia. [Epub ahead of print], 2014.
[Journal]
7)  Williams KM, Hnatiuk O, Mitchell SA, Baird K, Gadalla SM, Steinberg SM, Shelhamer J, Carpenter A, Avila D, Taylor T, Grkovic L, Pulanic D, Comis LE, Blacklock-Schuver B, Gress RE, Pavletic SZ.
NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT.
Bone Marrow Transplant. 49: 561-6, 2014.
[Journal]
8)  Williams JA, Zhang J, Jeon H, Nitta T, Ohigashi I, Klug D, Kruhlak MJ, Choudhury B, Sharrow SO, Granger L, Adams A, Eckhaus MA, Jenkinson SR, Richie ER, Gress RE, Takahama Y, Hodes RJ.
Thymic medullary epithelium and thymocyte self-tolerance require cooperation between CD28-CD80/86 and CD40-CD40L costimulatory pathways.
J. Immunol. 192: 630-40, 2014.
[Journal]
9)  Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Cole K, Taylor T, Avila D, Zhang D, Pulanic D, Grkovic L, Fowler D, Gress RE, Pavletic SZ.
Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.
Bone Marrow Transplant. 49: 116-21, 2014.
[Journal]
10)  Farthing DE, Buxbaum NP, Bare CV, Treadwell SM, Kapoor V, Williams KM, Gress RE.
A rapid and sensitive GC/MS triple quadrupole method to measure deuterium labeled deoxyadenosine in DNA from limited mouse cell populations.
Anal Chem. 85: 4613-4620, 2013.
[Journal]
11)  Bodogai M, Lee Chang C, Wejksza K, Lai J, Merino M, Wersto RP, Gress RE, Chan AC, Hesdorffer C, Biragyn A.
Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L.
Cancer Res. 73: 2127-38, 2013.
[Journal]
12)  Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma.
Clin. Cancer Res. 19: 2048-2060, 2013.
[Journal]
13)  Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood. 122: 4129-39, 2013.
[Journal]
14)  Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR.
Host Lymphocyte Depletion as a Strategy to Facilitate Early Full Donor Chimerism after Reduced-Intensity Allogeneic Stem Cell Transplantation.
Biol. Blood Marrow Transplant. 19: 1509-1513, 2013.
[Journal]
15)  Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ.
National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis.
Biol. Blood Marrow Transplant. 19: 632-9, 2013.
[Journal]
16)  Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR.
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
Bone Marrow Transplant. 48: 269-77, 2013.
[Journal]
17)  Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.
Phase II clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Blood. 121: 2864-2874, 2013.
[Journal]
18)  Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ.
Proceedings from the National Cancer Institute"s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.
Biol. Blood Marrow Transplant. 19: 1537-45, 2013.
[Journal]
19)  Kim GY, Ligons DL, Hong C, Luckey MA, Keller HR, Tai X, Lucas PJ, Gress RE, Park JH.
An In Vivo IL-7 Requirement for Peripheral Foxp3+ Regulatory T Cell Homeostasis.
J. Immunol. 188: 5859-66, 2012.
[Journal]
20)  Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Leukemia. 26: 633-43, 2012.
[Journal]
21)  Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood. 119: 2956-9, 2012.
[Journal]
22)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
[Journal]
23)  El-Kassar N, Flomerfelt FA, Choudhury B, Hugar LA, Chua KS, Kapoor V, Lucas PJ, Gress RE.
High levels of IL-7 cause dysregulation of thymocyte development.
Int. Immunol. 24: 661-71, 2012.
[Journal]
24)  Tomblyn M, Chen M, Kukreja M, Aljurf MD, Al Mohareb F, Bolwell BJ, Cahn J, Carabasi MH, Gale RP, Gress RE, Gupta V, Hale GA, Ljungman P, Maziarz RT, Storek J, Wingard JR, Young JH, Horowitz MM, Ballen KK.
No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation.
Transpl Infect Dis. 14: 468-478, 2012.
[Journal]
25)  Fassil H, Bassim CW, Mays J, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Hakim FT, Taylor T, Avila D, Zhang D, Grkovic L, Datiles M, Gress RE, Pavletic SZ.
Oral chronic graft-vs.-host disease characterization using the NIH scale.
J. Dent. Res. 91: 45S-51S, 2012.
[Journal]
26)  Memon SA, Sportès C, Flomerfelt FA, Gress RE, Hakim FT.
Quantitative analysis of T cell receptor diversity in clinical samples of human peripheral blood.
J. Immunol. Methods. 375: 84-92, 2012.
[Journal]
27)  Pollack M, Heugel J, Xie H, Leisenring W, Storek J, Young J, Kukreja M, Gress R, Tomblyn M, Boeckh M.
An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant Recipients.
Biology of Blood and Marrow Transplantation : journal of the American Society for Blood and Marrow Transplantation. 17: 664-673, 2011.
[Journal]
28)  Mackall CL, Fry TJ, Gress RE.
Harnessing the biology of IL-7 for therapeutic application.
Nat. Rev. Immunol. 11: 330-42, 2011.
[Journal]
29)  Hardy NM, Mossoba ME, Steinberg SM, Fellowes V, Yan XY, Hakim FT, Babb RR, Avila D, Gea-Banacloche J, Sportès C, Levine BL, June CH, Khuu HM, Carpenter AE, Krumlauf MC, Dwyer AJ, Gress RE, Fowler DH, Bishop MR.
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
Clin. Cancer Res. 17: 6878-87, 2011.
[Journal]
30)  Lucas PJ, Williams KM, Mella H, Williams JA, Telford W, Gress RE.
Rapid thymic epithelia preparation for single-cell analysis of complex thymus stromal cell populations.
MACS & more. 13: 25-29, 2011.
[Journal]
31)  Foster AD, Sivarapatna A, Gress RE.
The aging immune system and its relationship with cancer.
Aging health. 7: 707-718, 2011.
[Journal]
32)  Olkhanud PB, Rochman Y, Bodogai M, Malchinkhuu E, Wejksza K, Xu M, Gress RE, Hesdorffer C, Leonard WJ, Biragyn A.
Thymic stromal lymphopoietin is a key mediator of breast cancer progression.
J. Immunol. 186: 5656-62, 2011.
[Journal]
33)  Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A.
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells.
Cancer Res. 71: 3505-3515, 2011.
[Journal]
34)  ElKassar N, Gress RE.
An overview of IL-7 biology and its use in immunotherapy.
J Immunotoxicol. 7: 1-7, 2010.
[Journal]
35)  Bishop MR, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Sportes C, Gress RE, Fowler DH.
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Cancer. 116: 852-62, 2010.
[Journal]
36)  Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE.
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
Clin. Cancer Res. 16: 727-35, 2010.
[Journal]
37)  Park JH, Adoro S, Guinter T, Erman B, Alag AS, Catalfamo M, Kimura MY, Cui Y, Lucas PJ, Gress RE, Kubo M, Hennighausen L, Feigenbaum L, Singer A.
Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells.
Nat. Immunol. 11: 257-64, 2010.
[Journal]
38)  Lee DK, Hakim FT, Gress RE.
The thymus and the immune system: layered levels of control.
J Thorac Oncol. 5: S273-6, 2010.
[Journal]
39)  Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE, Pollack MS, Storek J, Thompson JC, Tiberghien P, Young JA, Ribaud P, Horowitz MM, Keating A.
Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research.
Biol. Blood Marrow Transplant. 15: 864-71, 2009.
[Journal]
40)  Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A.
Background to hematopoietic cell transplantation, including post transplant immune recovery.
Bone Marrow Transplant. 44: 457-62, 2009.
[Journal]
41)  Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, Deng J, Xu M, Briest S, Biragyn A.
Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.
Cancer Res. 69: 5996-6004, 2009.
[Journal]
42)  Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ.
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface.
Bone Marrow Transplant. 44: 453-5, 2009.
[Journal]
43)  Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Boeckh MA.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
Biol. Blood Marrow Transplant. 15: 1143-238, 2009.
[Journal]
44)  Confer D, Gress R, Tomblyn M, Ehninger G.
Hematopoietic cell graft safety.
Bone Marrow Transplant. 44: 463-5, 2009.
[Journal]
45)  Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT.
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.
Blood. 113: 3620-30, 2009.
[Journal]
46)  Sportès C, Gress RE, Mackall CL.
Perspective on potential clinical applications of recombinant human interleukin-7.
Ann. N. Y. Acad. Sci. 1182: 28-38, 2009.
[Journal]
47)  Kapoor V, Hakim FT, Rehman N, Gress RE, Telford WG.
Quantum dots thermal stability improves simultaneous phenotype-specific telomere length measurement by FISH-flow cytometry.
J. Immunol. Methods. 344: 6-14, 2009.
[Journal]
48)  Gress RE, Deeks SG.
Reduced thymus activity and infection prematurely age the immune system.
J. Clin. Invest. 119: 2884-7, 2009.
[Journal]
49)  Williams KM, Mella H, Lucas PJ, Williams JA, Telford W, Gress RE.
Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury.
Clin Transl Sci. 2: 279-85, 2009.
[Journal]
50)  Sportès C, Steinberg SM, Liewehr DJ, Gea-Banacloche J, Danforth DN, Avila DN, Bryant KE, Krumlauf MC, Fowler DH, Pavletic S, Hardy NM, Bishop MR, Gress RE.
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.
Biol. Blood Marrow Transplant. 15: 963-70, 2009.
[Journal]
51)  Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, Bishop MR.
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.
J Clin. Oncol. 26: 5735-5741, 2008.
[Journal]
52)  Williams KM, Lucas PJ, Bare CV, Wang J, Chu Y, Tayler E, Kapoor V, Gress RE.
CCL25 increases thymopoiesis following androgen withdrawal.
Blood. 112: 3255-3263, 2008.
[Journal]
53)  Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
Ann. Oncol. 19: 1935-1940, 2008.
[Journal]
54)  Chu Y, Schmitz S, Choudhury B, Telford W, Kapoor V, Garfield S, Howe D, Gress RE.
Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion.
Blood. 112: 2836-2846, 2008.
[Journal]
55)  Williams KM, Gress RE.
Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation.
Best practice & research. Clinical haematology. 21: 579-96, 2008.
[Journal]
56)  Chu YW, Gress RE.
Murine models of chronic graft-versus-host disease: insights and unresolved issues.
Biol. Blood Marrow Transplant. 14: 365-78, 2008.
[Journal]
57)  Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT.
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
Biol. Blood Marrow Transplant. 14: 290-300, 2008.
[Journal]
58)  Kochenderfer JN, Gress RE.
A comparison and critical analysis of preclinical anticancer vaccination strategies.
Exp. Biol. Med. (Maywood). 232: 1130-41, 2007.
[Journal]
59)  Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler DH, Gress RE, Bishop MR.
Host T Cells Affect Donor T Cell Engraftment and Graft-versus-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.
Biol. Blood Marrow Transplant. 13: 1022-30, 2007.
[Journal]
60)  Baatar D, Olkhanud P, Sumitomo K, Taub D, Gress R, Biragyn A.
Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL.
J. Immunol. 178: 4891-900, 2007.
[Journal]
61)  Hakim FT, Gress RE.
Immunosenescence: deficits in adaptive immunity in the elderly.
Tissue Antigens. 70: 179-89, 2007.
[Journal]
62)  Sportes C, Gress RE.
Interleukin-7 immunotherapy.
Adv. Exp. Med. Biol. 601: 321-33, 2007.
[Journal]
63)  Gress RE, Komanduri KV, Einsele H, Cooper LJ.
Lymphoid reconstruction and vaccines.
Biol. Blood Marrow Transplant. 13: 17-22, 2007.
[Journal]
64)  Kochenderfer JN, Chien CD, Simpson JL, Gress RE.
Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides.
Clin. Immunol. 124: 119-30, 2007.
[Journal]
65)  Williams KM, Hakim FT, Gress RE.
T cell immune reconstitution following lymphodepletion.
Semin. Immunol. 19: 318-30, 2007.
[Journal]
66)  Martin DL, Postan M, Lucas P, Gress R, Tarleton RL.
TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection.
Eur. J. Immunol. 37: 2764-71, 2007.
[Journal]
67)  Hakim FT, Gress RE.
Thymic involution: implications for self-tolerance.
Methods Mol. Biol. 380: 377-90, 2007.
[Journal]
68)  Kochenderfer JN, Simpson JL, Chien CD, Gress RE.
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.
Blood. 110: 450-60, 2007.
[Journal]
69)  Sugita S, Ng T, Lucas P, Gress R, Streilein J.
B7+ iris pigment epithelium induce CD8+ T regulatory cells; both suppress CTLA-4+ T cells.
J Immunol. 176: 118-127, 2006.
[Journal]
70)  Lucas PJ, Kim S, Mackall CL, Telford WG, Chu Y, Hakim FT, Gress RE.
Dysregulation of IL-15-mediated T cell homeostasis in TGF-{beta} dominant negative receptor transgenic mice.
Blood. 108: 2789-2795, 2006.
[Journal]
71)  Rosenberg S, Sportes C, Ahmadzadeh M, Fry T, Ngo L, Schwartz S, Stetler-Stevenson M, Morton K, Mavroukakis S, Morre M, Buffet R, Mackall C, Gress R.
IL-7 administration to humans leads to homeostatic expansion of CD8+ and CD4+ cells but not CD4+ T-regulatory cells.
J. Immunotherapy. 29: 313-319, 2006.
[Journal]
72)  Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant. 12: 1150-60, 2006.
[Journal]
73)  Kochenderfer JN, Chien CD, Simpson JL, Gress RE.
Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses.
J. Immunol. 177: 8860-73, 2006.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/18/2014.